A phase III study of Iressa [gefitinib] in combination with intravesical BCG versus intravesical BCG alone in high risk superficial transitional cell carcinoma of the bladder.
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2016
At a glance
- Drugs Gefitinib (Primary) ; BCG
- Indications Bladder cancer
- Focus Therapeutic Use
- 18 Dec 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Jan 2012 Actual end date (1 Jan 2012) added as reported by ClinicalTrials.gov.
- 09 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.